{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:39:05Z","timestamp":1786653545272,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>\n                    Antipsychotic medication-induced weight gain (AIWG) is a difficult-to-manage condition. Semaglutide is a widely used weight-lowering agent, but its role in AIWG has been evaluated in only few studies. This SRM evaluated if semaglutide can be effectively and safely used for AIWG in schizophrenia, bipolar disorder, and other psychiatric diseases. Electronic databases were searched for articles evaluating the use of semaglutide for managing AIWG. The primary outcome was reduction in body weight. Secondary outcomes were changes in body mass index (BMI), waist circumference (WC), HBA1c, metabolic parameters, and adverse events. Data from nine studies (44,233 participants; 4.21% diabetes; 94.79% euglycemia) which fulfilled all criteria were analysed. Semaglutide for AIWG was associated with a significant reduction in weight [mean difference (MD) -7.37 kg (95% confidence interval (CI): -12.39, -2.35);\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001; I\n                    <jats:sup>2<\/jats:sup>\n                    = 99%], BMI [MD -2.76 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    (95% CI: -4.15, -1.37);\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001; I\n                    <jats:sup>2<\/jats:sup>\n                    = 98%], WC [MD -5.12 cm (95% CI: -7.21, -3.03);\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001; I\n                    <jats:sup>2<\/jats:sup>\n                    = 76%], HbA1c [MD -0.35% (95% CI: -0.47, -0.24);\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001; I\n                    <jats:sup>2<\/jats:sup>\n                    = 91%] and higher &gt;5% weight loss [OR 2.25 (95% CI: 2.14, 2.36);\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.001; I\n                    <jats:sup>2<\/jats:sup>\n                    = 0%]. The occurrence of nausea, diarrhoea, and injection site reactions was similar. Vomiting was significantly higher in semaglutide users. The occurrence of psychiatric adverse events was lower in semaglutide users but not significant [OR 0.59 (95% CI: 0.33\u20131.07);\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.08; I\n                    <jats:sup>2<\/jats:sup>\n                    = 0%]. Semaglutide has good efficacy data with regard to quantum of weight loss with good safety for managing AIWG.\n                  <\/jats:p>","DOI":"10.4103\/ijem.ijem_1037_25","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:00:13Z","timestamp":1777568413000},"page":"119-128","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Semaglutide for Managing Antipsychotic-associated Weight Gain: A Systematic Review and Meta-analysis"],"prefix":"10.4103","volume":"30","author":[{"given":"Sweekruti","family":"Jena","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Kalinga Hospital, Bhubaneshwar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deep","family":"Dutta","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Center for Endocrinology Diabetes Arthritis and Rheumatism (CEDAR) Superspeciality Healthcare, Dwarka, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniruddha","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Central Institute of Psychiatry, Ranchi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameya","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Bhaktivedanta Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. B. M.","family":"Kamrul-Hasan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saptarshi","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Indraprastha Apollo Hospitals, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"R1-20260430","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: A randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"R2-20260430","doi-asserted-by":"crossref","first-page":"112556","DOI":"10.1016\/j.psychres.2019.112556","article-title":"Non-pharmacological interventions for preventing weight gain in patients with first episode schizophrenia or bipolar disorder: A systematic review","volume":"281","author":"Nyboe","year":"2019","journal-title":"Psychiatry Res"},{"key":"R3-20260430","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12888-016-1049-5","article-title":"Metformin in prevention and treatment of antipsychotic induced weight gain: A systematic review and meta-analysis","volume":"16","author":"de Silva","year":"2016","journal-title":"BMC Psychiatry"},{"key":"R4-20260430","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3389\/fphar.2018.01393","article-title":"Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain: A systematic review and network meta-analysis","volume":"9","author":"Zhuo","year":"2018","journal-title":"Front Pharmacol"},{"key":"R5-20260430","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00213-007-0731-1","article-title":"Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: A double-blind placebo-controlled study","volume":"192","author":"Poyurovsky","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"R6-20260430","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12012-020-09622-1","article-title":"Interrelated in vitro mechanisms of sibutramine-induced cardiotoxicity","volume":"21","author":"Alyu","year":"2021","journal-title":"Cardiovasc Toxicol"},{"key":"R7-20260430","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"R8-20260430","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"R9-20260430","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/biomedicines11030669","article-title":"Effect of glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors among obese\/overweight individuals treated with antipsychotic drug classes: An updated systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Patoulias","year":"2023","journal-title":"Biomedicines"},{"key":"R10-20260430","doi-asserted-by":"crossref","first-page":"102661","DOI":"10.1016\/j.eclinm.2024.102661","article-title":"GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: A living benefit-harm modelling study","volume":"73","author":"Moll","year":"2024","journal-title":"EClinicalMedicine"},{"key":"R12-20260430","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R13-20260430","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R14-20260430","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R16-20260430","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jclinepi.2021.08.022","article-title":"Cochrane\u2019s risk of bias tool for non-randomized studies (ROBINS-I) is frequently misapplied: A methodological systematic review","volume":"140","author":"Igelstr\u00f6m","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"R17-20260430","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"R18-20260430","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s11126-025-10137-7","article-title":"Semaglutide plus metformin versus metformin alone for antipsychotic-induced weight gain in patients with type 2 diabetes mellitus","volume":"96","author":"Vu","year":"2025","journal-title":"Psychiatr Q"},{"key":"R19-20260430","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1186\/s12888-024-06317-7","article-title":"Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): A non-randomised open-label pilot study","volume":"24","author":"Campforts","year":"2024","journal-title":"BMC Psychiatry"},{"key":"R20-20260430","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S2215-0366(25)00129-4","article-title":"Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): A phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia","volume":"12","author":"Siskind","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"R21-20260430","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbaf143","article-title":"Weight loss in veterans with schizophrenia and multimorbidity prescribed semaglutide: Results from a national retrospective cohort Study","author":"Browne","year":"2025","journal-title":"Schizophr Bull"},{"key":"R22-20260430","doi-asserted-by":"crossref","first-page":"20451253231165169","DOI":"10.1177\/20451253231165169","article-title":"Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - A case series","volume":"13","author":"Prasad","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"R23-20260430","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1007\/s12325-025-03261-0","article-title":"Obesity and schizophrenia: Results of a feasibility study with semaglutide to assist weight loss","volume":"42","author":"Heald","year":"2025","journal-title":"Adv Ther"},{"key":"R24-20260430","first-page":"e253639","article-title":"Semaglutide and early-stage metabolic abnormalities in individuals with schizophrenia spectrum disorders: A randomized clinical trial","author":"Sass","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"R25-20260430","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/jamapsychiatry.2025.2332","article-title":"Semaglutide Treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: The HISTORI randomized clinical trial","volume":"82","author":"Ganeshalingam","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"R26-20260430","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1038\/s41366-025-01885-4","article-title":"Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics","volume":"49","author":"Varghese","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"R27-20260430","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jrsm.1266","article-title":"Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: A comparison of new and existing tests","volume":"9","author":"Debray","year":"2018","journal-title":"Res Synth Methods"},{"key":"R28-20260430","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40345-025-00397-4","article-title":"Weight gain under antipsychotic and mood stabilizing treatment: A narrative review about mechanisms and future options","volume":"13","author":"Seiter","year":"2025","journal-title":"Int J Bipolar Disord"},{"key":"R29-20260430","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12991-020-00319-x","article-title":"Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: A randomized-controlled trial","volume":"19","author":"Wang","year":"2020","journal-title":"Ann Gen Psychiatry"},{"key":"R30-20260430","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/acps.13734","article-title":"Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis","volume":"150","author":"Bak","year":"2024","journal-title":"Acta Psychiatr Scand"},{"key":"R31-20260430","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.genhosppsych.2022.07.006","article-title":"A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis","volume":"78","author":"Lee","year":"2022","journal-title":"Gen Hosp Psychiatry"},{"key":"R32-20260430","first-page":"1","article-title":"A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain","author":"Menon","year":"2024","journal-title":"CNS Spectr"},{"key":"R33-20260430","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/oby.23946","article-title":"Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis","volume":"32","author":"Kushner","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"R34-20260430","doi-asserted-by":"crossref","first-page":"e13792","DOI":"10.1111\/obr.13792","article-title":"Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Kommu","year":"2024","journal-title":"Obes Rev"},{"key":"R35-20260430","doi-asserted-by":"crossref","first-page":"119670","DOI":"10.1016\/j.jad.2025.119670","article-title":"Depression and suicide\/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database","volume":"389","author":"Wang","year":"2025","journal-title":"J Affect Disord"},{"key":"R36-20260430","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jamainternmed.2024.4346","article-title":"Psychiatric safety of semaglutide for weight management in people without known major psychopathology: Post hoc analysis of the STEP 1, 2, 3, and 5 trials","volume":"184","author":"Wadden","year":"2024","journal-title":"JAMA Intern Med"},{"key":"R37-20260430","doi-asserted-by":"crossref","first-page":"e068652","DOI":"10.1136\/bmjopen-2022-068652","article-title":"Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: Study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)","volume":"13","author":"Sass","year":"2023","journal-title":"BMJ Open"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_1037_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:39:12Z","timestamp":1786649952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_1037_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_1037_25","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-12-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}